

How Pharmacovigilance Does Helps in Risk

Naga Navya Kalagoni, Pharmacovigilance specialist, United Pharma Technologies Inc, USA

***Corresponding Author:** Naga Navya Kalagoni, Pharmacovigilance specialist, United Pharma Technologies Inc, USA

Email: navyakalagoni4@gmail.com

Article Information

Article Type: Review Article
Article Received: 11-21-2020
Article Accepted: 12-23-2020
Article Published: 12-28-2020
Vol:1, Issue:1

Keywords: Drug Development, benefit-risk, Case Management, Adverse Events, Signal Detection, Data Entry, Clinical Trials

Introduction

Pharmacovigilance plays a major role before and after the drug development process. In this article, a detailed explanation of the pharmacovigilance activities and the benefit-risk evaluation has been discussed.

Every drug or medicinal product undergoes clinical phases when coming to the market approval, and they have a benefit-risk ratio of their own. Pharmacovigilance helps in providing the safety profile of the drug or medicinal product and finds the risks. It ensures the continued protection of medicinal products in the pharmaceutical and health care industries and aims to improve patient care and protection through the selection, monitoring, and communication of drug safety in relation to the use of medicines. Pharmacovigilance defines as "The science and activities relating to the detection, evaluation, understanding, and prevention of adverse reactions to medicines or any other medicine-related problems"^[4].

There are several steps in pharmacovigilance

Case receipt

Complete mail management, Checking the case validity (Identifiable patient, Identifiable reporter, the drug suspected of causing event, Ad-verse event), Translation of the AE report if needed.

Triage

Regulatory assessment of the adverse event, checking the seriousness of the case, Causality assessment as per the regulatory guidelines

Data entry

A case validity check, Duplicate check, Case creation in the database, a data entry from the adverse event report the safety database.

Case processing

Product, Event, and medical history coding with MedDRA and WHO-drug dictionaries. Labeling and Causality assessment, wiring narrative.

Quality review

Performing the quality review of the case is to ensure accurate data entry, case processing, medical history and product coding, review of the narrative.

Medical review

A medical reviewer confirms the adverse event coding, seriousness, and labeling of the events.

Reporting

There are two types of reporting Expediting and Periodic reporting. Expediting reports are submitted based on the severity of the event, whether or not the report had been already observed, and an evaluation of the relation of the event with the substance being administered. There is a timeframe to submit these reports, with life-threatening/Death/SUSARs are reported within 7 calendar days, and other serious cases are reported within 15 calendar days.

Periodic reports are submitted to the regulatory agency. It provides an aggregate summary and study of all records of adverse events obtained over a given period of time and offers an overall re-evaluation of safety at specified time points and lead to the continuing evaluation of whether improvements to product details or to the risk management strategy should be made. The time frame to report marketed products is for 3 years quarterly after approval^[5].

Analysis of individual cases and aggregate data establish a safety profile of a medication. The combined data collected from these reports will be used to help pharmacovigilance practitioners recognize possible safety signs by tracking emerging patterns. The research of the Council for International Organizations of Medical Sciences (CIOMS) on the benefit-risk evaluation of post-marketing medicinal products has led to a more comprehensive approach to assessing the merits of the medicinal products^[1].

Signal management helps to determine if a recently discovered drug or medicine related threats or whether known risks have changed and such steps are needed to reassess the drug safety profile^[3]. Investigations should be carried out to assess if the signal is a safety issue and what should be done with it. Signal management involves signal detection,

signal validation, signal prioritizing, signal assessment, a recommendation for action, and exchange of information ^[1]. Signals of medically relevant adverse reactions are taken from the spontaneous reports. Once the signal is taken, it involves the compilation and review of evidence from various sources. The signal will be tested for risk. A benefit-risk assessment is conducted, if the effect had a significant effect on the patient. The estimation of the benefit-risk is triggered by the presence of a clear indication, symptom, symptom-complex, or diagnosis, and one appears to limit the examination to the specific signal immediately ^[2]. However, in weighing the benefits and disadvantages of medication versus alternatives (or no treatment) with respect to a recent substantial risk, it is appropriate to analyze the effect of the new knowledge in the general sense of the drug.

Some of the steps to find out the risks are:

- Identify and characterize a safety profile of a drug/medicine.
- Indicate how the safety profile can be defined further in order to eliminate or reduce the risks involved with the use of the substance, log calculations.
- Document the post-authorization measurements that are mandatory at the time of granting market authorization as per approval.
- Clear summary of the product's safety profile and the efficacy of steps to mitigate the harm.
- Specify the efficacy of the drug used in the general community could also be found in the clinical population.

References

- [1] CIOMS. Practical aspects of signal detection in pharmacovigilance. Report of CIOMS Working Group VIII. 2008.
- [2] European Medicines Agency. Guideline on good pharmacovigilance practices (GVP) Module IX – Signal management (Rev 1). 2017.
- [3] Malikova, M. A. Practical applications of regulatory requirements for signal detection and communications in pharmacovigilance. Therapeutic Advances in Drug Safety. 2020;11: 2042098620909614.
- [4] World Health Organization. Essential Medicines and Health Products, Pharmacovigilance.
- [5] US Food & Drug Administration. Guidance for industry good pharmacovigilance practices and pharmacoepidemiologic assessment. 2005.